Department of Biological Sciences, KAIST, Daejeon, 34141, Republic of Korea.
Biotherapeutics Translational Research Center, KRIBB, Daejeon, 34113, Republic of Korea.
Adv Sci (Weinh). 2024 Oct;11(38):e2405593. doi: 10.1002/advs.202405593. Epub 2024 Aug 6.
Rapid and efficient cell line development (CLD) process is essential to expedite therapeutic protein development. However, the performance of widely used glutamine-based selection systems is limited by low selection efficiency, stringency, and the inability to select multiple genes. Therefore, an AND-gate synthetic selection system is rationally designed using split intein-mediated protein ligation of glutamine synthetase (GS) (SiMPl-GS). Split sites of the GS are selected using a computational approach and validated with GS-knockout Chinese hamster ovary cells for their potential to enable cell survival in a glutamine-free medium. In CLD, SiMPl-GS outperforms the wild-type GS by selectively enriching high producers. Unlike wild-type GS, SiMPl-GS results in cell pools in which most cells produce high levels of therapeutic proteins. Harnessing orthogonal split intein pairs further enables the selection of four plasmids with a single selection, streamlining multispecific antibody-producing CLD. Taken together, SiMPl-GS is a simple yet effective means to expedite CLD for therapeutic protein production.
快速高效的细胞系开发(CLD)过程对于加速治疗性蛋白的开发至关重要。然而,广泛使用的基于谷氨酰胺的选择系统的性能受到低选择效率、严格性以及无法选择多个基因的限制。因此,使用分裂内含子介导的谷氨酰胺合成酶(GS)的蛋白连接(SiMPl-GS)合理设计了 AND 门合成选择系统。GS 的分裂位点使用计算方法选择,并通过 GS 敲除中国仓鼠卵巢细胞进行验证,以评估其在无谷氨酰胺培养基中促进细胞存活的潜力。在 CLD 中,SiMPl-GS 通过选择性富集高产细胞,优于野生型 GS。与野生型 GS 不同,SiMPl-GS 导致大多数细胞产生高水平治疗蛋白的细胞池。利用正交分裂内含子对进一步实现了使用单个选择来选择四个质粒,简化了多特异性抗体产生的 CLD。总之,SiMPl-GS 是一种简单而有效的方法,可以加速治疗性蛋白生产的 CLD。
Biotechnol Bioeng. 2011-11-21
Biotechnol Prog. 2021-9
Exp Mol Med. 2023-4